<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622932</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-I-R</org_study_id>
    <nct_id>NCT02622932</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients</brief_title>
  <official_title>A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of [14C]
      Anlotinib in Patients With Advanced Cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">December 30, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative excretion of 14C-labeled Anlotinib (radioactivity in urine)</measure>
    <time_frame>up to 10 Days(endpoint when the two consecutive time points of cumulative excretion &lt;1%)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative excretion of 14C-labeled Anlotinib (radioactivity in feces)</measure>
    <time_frame>up to 10 Days(endpoint when the two consecutive time points of cumulative excretion &lt;1%)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excretion rate of 14C-labeled Anlotinib (radioactivity in urine)</measure>
    <time_frame>up to 10 Days(endpoint when the two consecutive time points of cumulative excretion &lt;1%)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Excretion rate of 14C-labeled Anlotinib (radioactivity in feces)</measure>
    <time_frame>up to 10 Days (endpoint when the two consecutive time points of cumulative excretion &lt;1%)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak Plasma Concentration(Cmax)</measure>
    <time_frame>up to 10 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Peak Plasma Concentration(Cmax),Cmax in ng/mL,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak time（Tmax）</measure>
    <time_frame>up to 10 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Peak time（Tmax）,Tmax in h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Half life（t1/2）</measure>
    <time_frame>up to 10 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Half life（t1/2）,t1/2 in h.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>up to 10 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Clearance（CL）</measure>
    <time_frame>up to 10 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Clearance（CL）,CL in L/h.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite identification of Anlotinib in plasma, urine and feces</measure>
    <time_frame>up to 10 Days(endpoint when the two consecutive time points of cumulative excretion &lt;1%)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Anlotinib and 14C-labeled Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each participant will be given a single dose of 14C-labeled gilteritinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib and 14C-labeled Anlotinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Anlotinib and 14C-labeled Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed and dated informed consent

          -  histologically or cytologically confirmed diagnosis of advanced solid tumor (including
             RCC、NSCLC、STS and CRC)

          -  failed to the treatment of line 1 or 2

          -  ECOG PS:0-1,Life expectancy of more than 3 months

          -  main organs function is normal

        Exclusion Criteria:

          -  prior treatment with Anlotinib or Allergic to drug or its formulation ingredients

          -  subjects with the gastrointestinal tract, liver and kidney disease of affect drug
             absorption and metabolism

          -  CTCAE(4.0) Grade 1 or higher non-remission toxicity induced by any other previous
             treatments

          -  patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2
             or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount
             of activities, affecting Instrumental activities of daily life])

          -  patients underwent major surgical treatment，open biopsy or significant traumatic
             injury within 28 days prior to assignment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihua Bao, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>April 27, 2019</last_update_submitted>
  <last_update_submitted_qc>April 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

